Millennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Millennium Management LLC raised its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 3.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,189,662 shares of the company’s stock after acquiring an additional 34,841 shares during the quarter. Millennium Management LLC owned approximately 1.74% of Replimune Group worth $14,407,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after acquiring an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after buying an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd grew its stake in shares of Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Replimune Group in the fourth quarter valued at $137,000. Finally, Freestone Grove Partners LP bought a new position in shares of Replimune Group in the fourth quarter valued at $140,000. 92.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Replimune Group news, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $260,168.74. Following the completion of the transaction, the director now directly owns 1,405,071 shares of the company’s stock, valued at $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the transaction, the insider now directly owns 146,933 shares of the company’s stock, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock valued at $603,655 over the last ninety days. 8.80% of the stock is currently owned by company insiders.

Replimune Group Trading Up 3.5%

REPL stock opened at $8.76 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The company has a fifty day moving average price of $8.69 and a two-hundred day moving average price of $11.24. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The stock has a market cap of $674.65 million, a price-to-earnings ratio of -2.85 and a beta of 0.68.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the company earned ($0.25) EPS. Equities analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright raised their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.